tiprankstipranks
Trending News
More News >
Nippon Shikizai, Inc. (JP:4920)
:4920
Japanese Market

Nippon Shikizai, Inc. (4920) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4920

Nippon Shikizai, Inc.

(4920)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 5.2)
Rating:68Neutral
Price Target:
¥1,284.00
▲(20.56% Upside)
Action:ReiteratedDate:09/04/25
The overall stock score of 68 reflects strong technical momentum and a reasonable valuation, despite financial performance challenges. The company's revenue growth is a positive indicator, but profitability and cash flow issues need addressing. The absence of significant earnings call data or corporate events means these factors did not influence the score.
Positive Factors
Diversified end markets
Serving cosmetics, pharmaceuticals and industrial applications gives durable revenue diversification across less-correlated end markets. This reduces dependence on any single cycle, supports cross-selling of specialty ingredients, and preserves long-term demand from structural beauty and healthcare trends.
Recent revenue expansion
A 17% year-over-year revenue increase to 2025 and multi-year top-line expansion reflect rising product adoption and market penetration. Sustained revenue growth supports economies of scale, improves bargaining power with suppliers, and provides a base to invest in R&D and margin improvement over the medium term.
Strong operating cash generation
Operating cash flow well above net income indicates core operations generate cash reliably, enabling working-capital funding and servicing interest despite accounting profit volatility. This operational cash strength is a durable buffer for reinvestment or gradual deleveraging if managed alongside capex and receivables.
Negative Factors
High leverage
A debt-to-equity ratio of 2.56 and low equity ratio signal material leverage, constraining financial flexibility. High indebtedness raises refinancing and interest-rate sensitivity, limiting the company’s ability to fund strategic investments or absorb demand shocks without additional capital or aggressive cash conversion.
Thin net margins
Low gross and especially net margins leave little cushion for cost inflation or pricing pressure. Modest EBIT/EBITDA margins limit internal funding for growth and make returns highly sensitive to raw-material cost swings, impairing long-term ability to finance innovation or absorb competitive pricing moves.
Negative free cash flow
Negative free cash flow despite strong operating cash indicates capex, working capital, or other outflows are consuming cash. Persistent FCF deficits force reliance on debt or equity financing, exacerbating leverage and reducing ability to sustain dividends or fund strategic projects without corrective operational or capital allocation changes.

Nippon Shikizai, Inc. (4920) vs. iShares MSCI Japan ETF (EWJ)

Nippon Shikizai, Inc. Business Overview & Revenue Model

Company DescriptionNippon Shikizai, Inc. researches and develops, manufactures, and sells cosmetics in Japan and internationally. The company offers lip products, such as lipsticks, and lip liners and glosses; eye products, including eye shadows, mascaras, eye liners, and eyebrow make-up products; and facial products comprising foundations, concealers, loose powders, blushes, and highlighters. It also provides skin care products, such as sunscreen and whitening products, scrubs, masks, and cleansers. The company was founded in 1930 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyNippon Shikizai generates revenue through the production and sale of its specialty chemicals and functional materials. The company has established multiple revenue streams, including direct sales to manufacturers in the cosmetics and pharmaceutical industries, where it supplies essential raw materials for product formulations. Additionally, Nippon Shikizai may engage in partnerships or collaborations with other firms, enhancing its market reach and product offerings. Factors contributing to its earnings include the demand for high-quality cosmetic ingredients, the growth of the pharmaceutical sector, and the continuous innovation in product development to meet changing consumer preferences.

Nippon Shikizai, Inc. Financial Statement Overview

Summary
Nippon Shikizai, Inc. shows strong revenue growth but faces challenges in profitability and cash flow. The high leverage is a financial risk, although operational cash flows are robust. Improvement in cost management and debt levels is crucial for financial stability.
Income Statement
70
Positive
The company's revenue has shown a strong upward trend, with significant growth from 2022 to 2025. Revenue growth rate from 2024 to 2025 was 17.17%. The gross profit margin for 2025 was 12.43%, indicating moderate profitability. However, the net profit margin declined to 1.23% in 2025, reflecting pressures on net earnings. EBIT and EBITDA margins were also modest, at 2.77% and 8.18% respectively, indicating room for operational efficiency improvements.
Balance Sheet
60
Neutral
The debt-to-equity ratio is elevated at 2.56 for 2025, suggesting a high leverage position, which could pose risks if not managed carefully. Return on equity improved to 5.68% in 2025, indicating better utilization of shareholder funds, but still leaves room for improvement. The equity ratio was 22.52%, showing a moderately leveraged balance sheet.
Cash Flow
55
Neutral
There was a negative free cash flow in 2025, which is a concern for liquidity. Free cash flow to net income ratio is negative, indicating cash flow challenges. Operating cash flow to net income ratio stands at 2.62, showing strong operational cash generation relative to net income. However, the decline in free cash flow growth is a potential risk.
BreakdownTTMFeb 2025Feb 2024Feb 2023Feb 2022Feb 2021
Income Statement
Total Revenue16.68B17.63B15.05B11.76B8.70B9.14B
Gross Profit2.06B2.19B2.02B1.39B804.24M402.55M
EBITDA1.24B1.44B1.29B1.11B783.38M193.08M
Net Income120.87M216.30M398.11M246.29M-122.03M-848.67M
Balance Sheet
Total Assets17.01B16.89B17.09B16.05B15.35B15.55B
Cash, Cash Equivalents and Short-Term Investments873.70M949.02M1.39B1.33B1.32B1.08B
Total Debt9.28B9.73B9.51B10.04B10.22B10.53B
Total Liabilities13.26B13.09B13.56B13.04B12.40B12.46B
Stockholders Equity3.75B3.80B3.53B3.01B2.95B3.09B
Cash Flow
Free Cash Flow0.00-572.15M567.48M332.14M533.27M-1.56B
Operating Cash Flow0.00567.79M1.25B615.40M781.34M405.52M
Investing Cash Flow0.00-1.11B-438.36M-252.81M-187.87M-2.08B
Financing Cash Flow0.0095.46M-697.50M-413.11M-338.23M1.87B

Nippon Shikizai, Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1065.00
Price Trends
50DMA
1171.02
Positive
100DMA
1120.15
Positive
200DMA
1075.36
Positive
Market Momentum
MACD
8.03
Positive
RSI
45.35
Neutral
STOCH
15.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4920, the sentiment is Neutral. The current price of 1065 is below the 20-day moving average (MA) of 1194.93, below the 50-day MA of 1171.02, and below the 200-day MA of 1075.36, indicating a neutral trend. The MACD of 8.03 indicates Positive momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 15.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4920.

Nippon Shikizai, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
¥161.73B19.225.00%1.41%0.75%
71
Outperform
¥88.54B26.456.83%3.53%3.05%-32.61%
68
Neutral
¥2.47B10.531.72%-6.06%-97.12%
66
Neutral
¥39.11B26.301.81%0.22%4.15%
63
Neutral
¥6.95B10.292.38%-0.79%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
58
Neutral
¥5.84B24.381.68%8.46%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4920
Nippon Shikizai, Inc.
1,178.00
62.11
5.57%
JP:4919
Milbon Co
2,793.00
-85.72
-2.98%
JP:4923
Cota Co., Ltd.
1,330.00
-145.08
-9.84%
JP:4925
HABA Laboratories, Inc.
1,839.00
79.77
4.53%
JP:4926
C'BON COSMETICS Co., Ltd.
1,365.00
212.37
18.42%
JP:4928
Noevir Holdings Co., Ltd.
4,735.00
710.34
17.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 04, 2025